The New England journal of medicine 2018-12-06
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
Abstract
Background
Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)-programmed death 1 (PD-1) signaling has shown promise in the treatment of extensive-stage small-cell lung cancer. Combining checkpoint inhibition with cytotoxic chemotherapy may have a synergistic effect and improve efficacy.
Methods
We conducted this double-blind, placebo-controlled, phase 3 trial to evaluate atezolizumab plus carboplatin and etoposide in patients with extensive-stage small-cell lung cancer who had not previously received treatment. Patients were randomly assigned in a 1:1 ratio to receive carboplatin and etoposide with either atezolizumab or placebo for four 21-day cycles (induction phase), followed by a maintenance phase during which they received either atezolizumab or placebo (according to the previous random assignment) until they had unacceptable toxic effects, disease progression according to Response Evaluation Criteria in Solid Tumors, version 1.1, or no additional clinical benefit. The two primary end points were investigator-assessed progression-free survival and overall survival in the intention-to-treat population.
Results
A total of 201 patients were randomly assigned to the atezolizumab group, and 202 patients to the placebo group. At a median follow-up of 13.9 months, the median overall survival was 12.3 months in the atezolizumab group and 10.3 months in the placebo group (hazard ratio for death, 0.70; 95% confidence interval [CI], 0.54 to 0.91; P=0.007). The median progression-free survival was 5.2 months and 4.3 months, respectively (hazard ratio for disease progression or death, 0.77; 95% CI, 0.62 to 0.96; P=0.02). The safety profile of atezolizumab plus carboplatin and etoposide was consistent with the previously reported safety profile of the individual agents, with no new findings observed.
Conclusions
The addition of atezolizumab to chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer resulted in significantly longer overall survival and progression-free survival than chemotherapy alone. (Funded by F. Hoffmann-La Roche/Genentech; IMpower133 ClinicalTrials.gov number, NCT02763579 .).
Related Questions
Does omission of PCI influence your decision whether to offer consolidative thoracic radiation in ES-SCLC after chemo + immunotherapy?
This is one of those stories that has evolved over time with our improvements in technology.EORTC 08993 (the Slotman study) demonstrated both an improvement in the rate of symptomatic brain mets at 1 yr from 40% to 15%, and an improvement in 1 yr OS from 13% to 27%. However, a huge caveat here is th...
Do you recommend trilaciclib as primary prophylaxis for myelosuppression in certain patients with ES-SCLC treated with first line chemo-immunotherapy?
I do not routinely use growth factor support nor trilaciclib with chemotherapy or chemo-immunotherapy for people with ES-SCLC. My starting doses of chemo are usually carboplatin AUC 5 day 1 + etoposide 100 mg/m2 days 1-3, and the degree of myelosuppression and incidence of neutropenic fever with thi...
Do the results of CheckMate 451 (nivo-ipi or nivo maintenance after chemotherapy in patients with SCLC) raise any questions for you about the role of immunotherapy in SCLC as established by the CASPIAN and IMpower 133 trials?
The results of the Checkmate 451 trial evaluating nivolumab and ipilimumab or nivolumab maintenance versus no maintenance following front line chemotherapy for extensive stage small cell lung cancer help put the CASPIAN and IMpower 133 trials using front line chemotherapy with immune checkpoint inhi...
How do you approach the treatment of patients with widespread ES-SCLC with a poor performance status?
My basic philosophy for the initial treatment of people with ES-SCLC (or LS-SCLC) with poor PS is to just try to get them going in the right direction without killing them with my treatment. SCLC is usually very responsive to chemotherapy, so you don’t have to beat people with full doses of the drug...
When would you ever choose cisplatin over carboplatin in extensive stage small cell lung cancer?
I prefer carboplatin over cisplatin in ES SCLC as there does not seem to be proven benefit and there is certainly higher risk for toxicity. There was a recent report at ASCO with similar findings. I reserve cisplatin for limited stage disease with concurrent radiation or as adjuvant therapy in cases...
Would you consider adding atezolizumab to chemotherapy for metastatic esophageal small cell cancer?
I would consider adding atezolizumab (and indeed I have in the past). Of course, this would be based on the SCLC literature from the IMpower133 and CASPIAN trials where atezolizumab and durvalumab respectively improved outcomes when combined with platinum/etoposide chemotherapy. But there is a cavea...
Are there any data to guide choice of immunotherapy agent in first line treatment for extensive stage small cell lung cancer?
Both the addition of durvalumab and atezolizumab to platinum etoposide resulted in a modest improvement in median progression free, overall survival and saw twelve-month overall survival rates just above 50%. The ECOG-ACRIN phase II trial of nivolumab added to platinum etoposide also improved PFS an...
Would you withhold immunotherapy for ES-SCLC during the COVID-19 pandemic?
Risks of COVID-19 infection and severe pneumonia seem to be higher in our patients with lung cancer. This is fairly early data and some of the patients included in those analyses were not receiving any active therapy. This suggests that at least some of the risk is simply frequent visits to the canc...
Do you recommend prophylactic cranial irradiation for ES-SCLC patients now that immunotherapy is included in the treatment schema?
I do not pursue PCI for most patients with extensive stage SCLC. We know the EORTC phase III study led by Ben Slotman (NEJM 2007) showed a decrease in the cumulative risk of brain metastases that translated into a survival benefit. One of the flaws of the study was the lack of baseline and regular M...
What treatment would you consider for ES-SCLC that is refractory to first-line platinum plus immunotherapy?
Tarlatamab is my go-to in this setting. However, I think there are still good questions about who are the best patients to treat with tarlatamab. Chemorefractory patients are generally ideal for tarlatamab as was stated before, it is a different mechanism of action than chemotherapy and the response...
Are you testing for PD-L1 IHC expression in extensive stage small cell lung cancer who are planned to be treated with chemotherapy plus immunotherapy?
Based on trial approved chemo-immunotherapy for ES-SCLC, it is not a requirement. IMpower33 (Atezo) and Caspian trial (durva).
How would you approach maintenance therapy following chemo-immunotherapy for extensive-stage small cell lung cancer per the IMPower133 trial if there is a mixed response post-treatment but clearly some clinical benefit?
The definition of clinical benefit remains a very subjective one. We presume that the patient has had an overall good response to the combination of chemotherapy and immunotherapy, and has undergone restaging imaging during the immunotherapy alone maintenance stage. The above question would suggest ...
How would you treat a patient with extensive-stage small cell carcinoma and severe end-stage COPD on home oxygen?
I would base this decision on the patient's performance status, not solely on a diagnosis of COPD or the use of supplemental oxygen. While the IMpower 133 trial included patients with ECOG PS of 0-1, in the outpatient setting I would generally offer chemoimmunotherapy to a patient with PS 0-2. Pneum...
Would you offer WBRT to a patient with ES-SCLC with improving brain mets on immunotherapy?
The answer to this question arises more from the domains of personal opinion and anecdotal experience rather than a strong evidence basis. The study establishing the value of atezolizumab in this setting (N Engl J Med 2018) does not provide data specific to informing a management approach.At my own ...
For metastatic large cell neuroendocrine carcinoma of lung, would you treat as small cell with platinum/etoposide/atezolizumab or would you treat as NSCLC and use platinum doublet/pembrolizumab?
Can consider NGS and treat like SCLC if there is Rb/p53 mutation pattern and NSCLC if STK11/KEAP1 pattern (later prob Immunotherapy resistant?) https://www.esmo.org/Conferences/Past-Conferences/ESMO-2017-Congress/News-Articles/Improved-Survival-Demonstrated-with-NSCLC-chemotherapy-in-Pulmonary-Lar...
As consolidative thoracic radiation (cTRT) was prohibited on the seminal chemoimmunotherapy trials in ES-SCLC, how do you approach cTRT in practice?
The data supporting consolidation thoracic radiotherapy (cTRT) after chemotherapy response in ES-SCLC are relatively soft. The phase III Jeremic trial (Jeremic et al., PMID 10561263) reported an overall survival (OS) improvement with accelerated hyperfractionated cTRT to 54 Gy + daily carboplatin/et...
In light of recent data suggesting limited activity of Atezolizumab monotherapy in the 2nd line treatment of ES-SCLC, would you still offer Atezolizumab maintenance following combination chemo-IO in the first line setting?
The data as single agent therapy in the second line setting should not impact decisions regarding front line therapy. In IMpower133 patients randomized to chemotherapy and atezolizumab continued on atezolizumab if they had stable disease following completion of the chemotherapy plus atezolizumab. Th...
How do you sequence thoracic consolidation RT and PCI with incorporation of immunotherapy in ES-SCLC?
In the IMpower133 study, "during the maintenance phase, prophylactic cranial irradiation was permitted as per local standard-of-care, but thoracic radiation with curative intent or the intent to eliminate residual disease was not permitted. Palliative thoracic radiation was allowed. (quoting from th...
How do you chose between 4 or 6 cycles of chemotherapy in patients with small cell lung cancer?
Very good question made a bit more straightforward with the publication in NEJM of IMpower 133 for extensive stage disease and recently added to NCCN guidelines as a category 1, preferred first line therapy in ES-SCLC. I typically follow the four cycles as used in IMpower 133 for patients with exten...
Is it acceptable to treat newly diagnosed small cell lung cancer with limited brain metastasis with upfront SRS?
First, to be clear, there's not good evidence regarding the role of radiosurgery in small cell patients who have not had WBRT or PCI. In patients without brain metastases, there's a clearly defined and clinically significant survival benefit, which seems to result from both control of existing metas...